20th Annual · February 2022 · Virtual
2022
- 33 faculty
- 3 recordings
- 10:00Introductory Notes on the 20th Annual MCI Symposium
- 10:15Reflection on the Concept of MCI and the Evolution of the Term “Adult Cognitive Disorders”
10:35
- 10:40Keynote The Global Effort to Study the Short-and Long-term consequences of SARS-CoV-2 on the CNS
- 11:10Clinical Features and Plasma Biomarkers of Neurodegeneration and Neuroinflammation in Hospitalized COVID-19 Patients
- 11:30Pathogenesis and Neurological Manifestations of COVID-19 Infection
- 11:50Neurologic Post-acute Sequelae of SARS-CoV-2 Infection
- 12:10Impact of COVID on Persons with AD: Focus on Hispanics/Native Americans
- 12:30Panel Discussion/Q&A
- 12:50Break
13:00
- 13:05Keynote Symptomatic, Cognitive and Biomarker Heterogeneity in the Preclinical and Prodromal Stages of Alzheimer’s Disease
- 13:35LATE: What It Is and Relevance to MCI
- 13:55
- 14:15A Multiomics Approach to Heterogeneity in Alzheimer’s
- 14:35Embracing Heterogeneity in Early-phase Clinical Trial Designs for AD/ADRD
- 14:55Panel Discussion/Q&A
- 15:15End of Day 1
10:00
Session 3
Predicting Progression & Cognitive Decline in AD and Impact on Clinical Trial Design
Chair: Philip Scheltens, MD, PhDAmsterdam University Medical Centers
- 10:05Keynote Regional Accumulation of Tau in the Brain is a Major Determinant of Rate of Progression
- 10:35Novel Approaches to Efficiently Identify Progression to SCD and MCI for AD Clinical Research
- 10:55The Role of Brain Connectivity in the Spreading of Tau Pathology in AD
- 11:15
- 11:35Incorporating Factors Associated with Rate of Progression into the Design of AD Clinical Trials
- 11:55Improved Designs for AD Clinical Treatment Trials
- 12:15Panel Discussion/Q&A
- 12:35Break
12:45
- 12:50Keynote Will Targeting Neuropsychiatric Symptoms in Prodromal AD Delay or Prevent Progression to Dementia?
- 13:20Challenges in the Measurement of Neuropsychiatric Symptoms (NPS) in MCI and Dementia (Caregiver Report and Objective Assessment)
- 13:40Association of Biomarkers (sMRI, fMRI, FDG-PET, Amyloid PET, Tau PET) with Neuropsychiatric Symptoms in MBI, MCI and Dementia
- 14:00Mild Behavioral Impairment, Prevalence, Caregiver Burden and Management
- 14:20
- 14:40Panel Discussion/Q&A
- 15:00
- 15:15END OF SYMPOSIUM
- 1:30 pm
- 1:35
- 1:35Topic introduction (effect of the pandemic on patients, managing neuropsychiatric challenges, life after COVID)
- 1:55Drugs: What’s New, What’s Working, What's on the Horizon?
- 1:55Topic introduction
- 2:15
- 2:15Topic introduction (difference between MCI and AD, predicting rate of progression; neuropsychiatric feaures)
- 2:35Screening for Alzheimer’s Disease
- 2:35Topic introduction
- 2:55
- 2:55Topic introduction
- 3:30Concluding Remarks
Care Partner Forum
Sunday, March 6, 2022
- 3:45 PM
- 3:55 PMFinding and accepting support
- 3:55 PMTopic introduction
- 4:00 PMPresentation of caregiver feedback and discussion
- 4:20 PMStaying well while providing care
- 4:20 PMTopic introduction
- 4:25 PMPresentation of caregiver feedback and discussion
- 4:45 PMEnd of life (EOL)/palliative care
- 4:45 PMTopic introduction
- 4:50 PMPresentation of caregiver feedback and discussion
- 5:10 PMValue of participating in research
- 5:10 PMTopic introduction
- 5:15 PMPresentation of caregiver feedback and discussion
- 5:35 PMConcluding Remarks
- 5:45 PMEnd of the Forum
Programs, recordings and slides as published at the time. Slides and recordings appear only where speakers chose to share them. Affiliations are as of 2022.